Welcome to our dedicated page for SS Innovations International SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SS Innovations International's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SS Innovations International's regulatory disclosures and financial reporting.
SS Innovations International, Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $11,101,366 from $5,120,610 a year earlier, driven mainly by higher system sales.
The company posted a net loss of $3,582,571, improving from a $5,681,353 loss, with results heavily affected by non-cash stock compensation of $3,144,315 and depreciation of $323,747. Cash, cash equivalents and restricted cash increased to $24,005,680, helped by a private placement that generated net proceeds of $18,446,498.
Despite a working capital surplus of $40,216,514, management disclosed that recurring losses, dependence on related-party funding, and insufficient projected cash flows raise substantial doubt about the company’s ability to continue as a going concern over the next 12 months, absent additional financing and successful execution of growth plans.
SS Innovations International, Inc. reported a milestone demonstration of its robotic telesurgery technology. The company announced a successful long-distance cross-border procedure using the SSi Mantra surgical robotic system and the SSi MantrAsana tele-surgeon console, connecting a surgeon in Perth, Australia with a patient in Indore, India over more than 4,500 miles.
On May 2, 2026, Dr. Mohit Bhandari remotely performed a robotic gastrojejunostomy during the Royal Australian College of Surgeons Annual Scientific Congress using the portable SSi MantrAsana console. The company notes that more than 170 telesurgeries, including complex cardiac procedures, have now been completed with SSi Mantra, which has been clinically validated in India in over 100 types of surgical procedures.
SS Innovations International, Inc. reported that more than 10,500 cumulative surgeries have been successfully performed using its SSi Mantra surgical robotic system as of April 30, 2026. These include over 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries across multiple specialties.
The company has installed more than 200 SSi Mantra systems in eleven countries and trained approximately 2,100 physicians, with the platform used in over 170 different procedure types. Management highlights technology features, user-friendliness, and cost advantages as drivers of adoption since commercial launch in August 2022.
SS Innovations International, Inc. reports amended beneficial ownership by Sudhir Srivastava and Sushruta PVT LTD. Sudhir Srivastava beneficially owns 114,490,054 shares, representing 55.8% of the outstanding common stock. Sushruta PVT LTD holds 109,585,767 shares, representing 54.7%. The percentages are calculated using 200,231,535 shares outstanding as of March 9, 2026, per the company’s amended Form 10-K/A. The filing states Dr. Srivastava has a 100% interest in Sushruta PVT LTD and that his reported position includes options to purchase 4,872,287 shares and a direct holding of 32,000 shares.
SS Innovations International, Inc. filed a shelf S-3 registration to offer up to $150,000,000 of securities and to register up to 5,016,500 shares of common stock for resale by selling shareholders. The 5,016,500 Shares include 4,474,833 issued in a March 6, 2026 private placement and shares underlying warrants of 41,667 (RCP Warrants, $3.45 exercise) and 500,000 (HCW Warrants, $8.89 exercise). The prospectus states the company will not receive proceeds from selling shareholders’ resale; proceeds to the company will arise only if the warrants are exercised. The company reports a Nasdaq close of $4.02 on April 30, 2026 and that Chairman/CEO Dr. Sudhir Srivastava, through Sushruta Pvt Ltd., beneficially controls approximately 55.85% of the voting power.
SS Innovations International, Inc. filed an 8-K to share a press release about its vision for new surgical robotic technologies unveiled at the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India, which the Company recently hosted.
The Company highlighted four main innovations under development: the SSi Vimana Aero drone-based surgical system, the SSi Avtara humanoid surgical platform, the SSi Operion mobile operating room, and new single-arm robotic endoscopy and ultrasound assist carts. These concepts emphasize remote, mobile and teleoperated care in challenging environments.
At SMRSC 2026, more than 1,600 in-person and 1,800 virtual participants from 19 nations attended. Expert physicians performed 10 live telesurgeries and 13 live robotic surgeries using the Company’s existing SSi Mantra system across multiple specialties. The filing also reiterates standard forward-looking statement cautions.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported an indirect transfer of 10,000 shares of common stock as a bona fide gift. The shares were held by Sushruta Pvt. Ltd., an entity in which he has a controlling interest.
Following this non-market gift transaction, entities associated with Srivastava indirectly hold 109,585,767 shares of SS Innovations common stock. The filing reflects a routine personal transfer with no sale proceeds or open-market trading activity.
SS Innovations International, Inc. is hosting the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India from April 9–11, 2026. This third installment will gather surgeons, innovators and healthcare leaders to discuss the future of robotic and minimally invasive surgery.
Attendance is expected to exceed last year’s event, which drew more than 1,400 in-person attendees and 600 virtual participants from 17 nations. The conference will feature live telesurgeries, robotic surgeries, technology demonstrations and expert panels. The company highlights its SSi Mantra surgical robotic system, which has been clinically validated in India across more than 100 types of procedures.
SS Innovations International, Inc. insider Barry F. Cohen, COO – Americas and director, tendered 19,000 shares of common stock at a value of $5.58 per share to a non‑affiliated third-party lender. The shares were used to satisfy principal and interest owed on a $100,000 promissory note. Following this non‑market restructuring transaction, Cohen directly holds 7,780,088 shares of SS Innovations common stock.